House lawmaker seeks more documents in FDA criminal office inquiryWASHINGTON (Reuters) - A top U.S. lawmaker accused the Food and Drug Administration on Friday of failing to hand over documents that would show whether its criminal office is fulfilling the critical mission of protecting public health. “The FDA’s long-overdue response leaves key questions unanswered about the performance and effectiveness of the FDA’s Office of Criminal Investigations,” House of Representatives Energy and Commerce Committee Chairman Greg Walden told Reuters in a statement. An FDA spokeswoman did not have an immediate comment. Walden’s comments come about four months after the congressional panel launched an examination into the criminal office and how it was managing cases involving food, drugs and devices. The review came after Reuters reported that FDA agents were concerned that managers, including former OCI Director George Karavetsos, were forcing them to pursue often toothless cases involving mislabeled foreign-imported injectable drugs, at the expense of cases with more potential to protect the public health. The agents said they had become the “Botox Police” and were spending hours chasing down doctors who purchased authentic versions of Allergan’s popular anti-wrinkle drug that were labeled for use in other countries. Those concerns came at a time when the office was seeing more than half its opened cases ultimately get closed without action, Reuters found. Reuters also reported on how the FDA permitted Karavetsos to relocate back to Florida in mid-2016 and run the OCI from its Miami office, even after the FDA had already paid more than $25,000 to move him to Maryland in 2015. The FDA did not meet the committee’s October deadline to provide written answers to questions until Jan. 19. The next day, Karavetsos departed to work for DLA Piper where he will represent drug and device industry clients. In its letter reviewed by Reuters, the FDA listed its investigative priorities and said that traditional metrics used to gauge success, such as arrests and convictions, cannot capture the impact of its public health mission. It also provided annual data on arrests, convictions, and the number of opened cases. However, it omitted preliminary-stage investigative numbers from the total number of cases opened each year, which makes the conviction rate appear higher, according to a side-by-side comparison. Walden said the FDA did not provide a performance plan, among other things. He also complained of redactions on a separate record, which according to a committee aide contained salary and compensation information for Karavetsos. politicsNews
house lawmaker seeks documents fda criminal office inquirywashington reuters a top lawmaker accused food drug administration friday failing hand documents would show whether criminal office fulfilling critical mission protecting public health the fda response leaves key questions unanswered performance effectiveness fda office criminal investigations house representatives energy commerce committee chairman greg warden told reuters statement an fda spokeswoman immediate comment warden comments come four months congressional panel launched examination criminal office managing cases involving food drugs devices the review came reuters reported fda agents concerned managers including former oci director george karavetsos forcing pursue often worthless cases involving mislabeled injectable drugs expense cases potential protect public health the agents said become book police spending hours chasing doctors purchased authentic versions alderman popular drug labeled use countries those concerns came time office seeing half opened cases ultimately get closed without action reuters found reuters also reported fda permitted karavetsos relocate back florida run oci miami office even fda already paid move maryland the fda meet committee october deadline provide written answers questions the next day karavetsos departed work dla piper represent drug device industry clients in letter reviewed reuters fda listed investigative priorities said traditional metrics used gauge success arrests convictions capture impact public health mission it also provided annual data arrests convictions number opened cases however omitted investigative numbers total number cases opened year makes conviction rate appear higher according comparison warden said fda provide performance plan among things he also complained reactions separate record according committee aide contained salary compensation information karavetsos politicsnews
Your task is to classify the provided input as real or fake news. Label 0 is meant for fake news, Label 1 is for real news. TEXT: House lawmaker seeks more documents in FDA criminal office inquiryWASHINGTON (Reuters) - A top U.S. lawmaker accused the Food and Drug Administration on Friday of failing to hand over documents that would show whether its criminal office is fulfilling the critical mission of protecting public health. “The FDA’s long-overdue response leaves key questions unanswered about the performance and effectiveness of the FDA’s Office of Criminal Investigations,” House of Representatives Energy and Commerce Committee Chairman Greg Walden told Reuters in a statement. An FDA spokeswoman did not have an immediate comment. Walden’s comments come about four months after the congressional panel launched an examination into the criminal office and how it was managing cases involving food, drugs and devices. The review came after Reuters reported that FDA agents were concerned that managers, including former OCI Director George Karavetsos, were forcing them to pursue often toothless cases involving mislabeled foreign-imported injectable drugs, at the expense of cases with more potential to protect the public health. The agents said they had become the “Botox Police” and were spending hours chasing down doctors who purchased authentic versions of Allergan’s popular anti-wrinkle drug that were labeled for use in other countries. Those concerns came at a time when the office was seeing more than half its opened cases ultimately get closed without action, Reuters found. Reuters also reported on how the FDA permitted Karavetsos to relocate back to Florida in mid-2016 and run the OCI from its Miami office, even after the FDA had already paid more than $25,000 to move him to Maryland in 2015. The FDA did not meet the committee’s October deadline to provide written answers to questions until Jan. 19. The next day, Karavetsos departed to work for DLA Piper where he will represent drug and device industry clients. In its letter reviewed by Reuters, the FDA listed its investigative priorities and said that traditional metrics used to gauge success, such as arrests and convictions, cannot capture the impact of its public health mission. It also provided annual data on arrests, convictions, and the number of opened cases. However, it omitted preliminary-stage investigative numbers from the total number of cases opened each year, which makes the conviction rate appear higher, according to a side-by-side comparison. Walden said the FDA did not provide a performance plan, among other things. He also complained of redactions on a separate record, which according to a committee aide contained salary and compensation information for Karavetsos. politicsNews
Your task is to classify the provided input as real or fake news. Label 0 is meant for fake news, Label 1 is for real news. TEXT: house lawmaker seeks documents fda criminal office inquirywashington reuters a top lawmaker accused food drug administration friday failing hand documents would show whether criminal office fulfilling critical mission protecting public health the fda response leaves key questions unanswered performance effectiveness fda office criminal investigations house representatives energy commerce committee chairman greg warden told reuters statement an fda spokeswoman immediate comment warden comments come four months congressional panel launched examination criminal office managing cases involving food drugs devices the review came reuters reported fda agents concerned managers including former oci director george karavetsos forcing pursue often worthless cases involving mislabeled injectable drugs expense cases potential protect public health the agents said become book police spending hours chasing doctors purchased authentic versions alderman popular drug labeled use countries those concerns came time office seeing half opened cases ultimately get closed without action reuters found reuters also reported fda permitted karavetsos relocate back florida run oci miami office even fda already paid move maryland the fda meet committee october deadline provide written answers questions the next day karavetsos departed work dla piper represent drug device industry clients in letter reviewed reuters fda listed investigative priorities said traditional metrics used gauge success arrests convictions capture impact public health mission it also provided annual data arrests convictions number opened cases however omitted investigative numbers total number cases opened year makes conviction rate appear higher according comparison warden said fda provide performance plan among things he also complained reactions separate record according committee aide contained salary compensation information karavetsos politicsnews